Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Allopurinol in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* The patient is willing and able to provide informed consent~* Clinical diagnosis of chronic heart failure~* Ejection fraction (EF) \< 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography~* No significant coronary disease at cardiac catheterization~* New York Heart Association (NYHA) Class I-IV symptoms~* Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.~Exclusion Criteria:~* Metallic implant prohibiting magnetic resonance (MR) evaluation~* Inability to lie flat for MR study~* Administration of additional investigational drugs~* Calculated creatinine clearance \< 50 mL/min~* Allergy to allopurinol~* Current gout flare~* Currently taking oral allopurinol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: EXPERIMENTAL): One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
- Placebo (Type: PLACEBO_COMPARATOR): One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).